Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2018 16:05 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (Nasdaq:CKPT), a Fortress Biotech (Nasdaq:FBIO) company, today announced that it is...
February 06, 2018 08:30 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics to Present at BIO CEO & Investor Conference

NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that James F. Oliviero, President...
January 03, 2018 07:30 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics to Present at Biotech Showcase™ 2018

NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that President and Chief Executive...
December 14, 2017 07:30 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018

NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that its senior management team will...
October 05, 2017 07:30 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301

NEW YORK, Oct. 05, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that the first patient has been...
September 20, 2017 08:00 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference

NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that James F. Oliviero, President...
September 11, 2017 08:30 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer

NEW YORK, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that the U.S. Food and Drug...
September 05, 2017 08:00 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

NEW YORK, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that James F. Oliviero, President...
June 26, 2017 08:00 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics Commences Trading on the NASDAQ Capital Market

NEW YORK, June 26, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company focused on the acquisition, development and...
June 01, 2017 08:00 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

NEW YORK, June 01, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (OTCQX:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that James F. Oliviero, President and...